Takeda Augments Io Portfolio With Third Build-To-Buy Acquisition In A Year

Takeda Added Some More Firepower To Its Immuno-Oncology Game On Monday When The Japanese Giant Announced It Will Exercise Its Option To Acquire U.K.-Based Adaptate Biotherapeutics.The Planned Acquisition Will Give Takeda Full Access To Adaptate